Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is to evaluate the efficacy and safety of combination of Camrelizumab (Immunotherapy, PD-1 inhibitor), Fluzoparib (PARP inhibitor) and Nab-paclitaxel in neoadjuvant therapy of Her-2 negative breast cancer patients with HRR gene mutation.
This is a prospective, single-center, open-label phase II clinical trial investigating the activity of Camrelizumab+Fluzoparib+Nab-paclitaxel combination therapy in breast cancer patients with Her2-negative and HRR gene mutation for neoadjuvant therapy.
Anticipated 66 candidates meeting all study eligibility criteria will receive 8 cycles of Nab-paclitaxel (260mg/m2) every 3 weeks, which will add Camrelizumab (200mg, d1) and Fluzoparib (100mg BID) from the second cycle.
HRR gene mutation contains at least one pathogenic or likely pathogenic variant in germline or somatic BRCA1, BCRA2 and PALB2 genes, or in germline ATM, BARD1, BRIP1, CDK12, CHEK2, RAD51C, RAD51D genes.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Camrelizumab, Fluzoparib and Nab-paclitaxel | Experimental | Participants who confirmed pathogenic or likely pathogenic HRR gene mutation received Camrelizumab and Fluzoparib with nab-paclitaxel from the second cycle followed by nab-paclitaxel for one cycle. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Camrelizumab | Drug | Camrelizumab at a fixed dose of 200mg via IV infusion on Days 1 each 21-day cycle. Fluzoparibat at a fixed dose of 100mg BID, each 21-day cycle. Nab-paclitaxel at a fixed dose of 260 milligrams via intravenous (IV) infusion on Days 1 each 21-day cycle. |
| Measure | Description | Time Frame |
|---|---|---|
| Pathologic Complete Response (pCR) | Pathologic response will be assessed in the surgically resected cancer and lymph nodes after completion of all chemotherapy by the local pathologist as part of routine care. Pathologic complete response is defined as no invasive cancer in the resected breast tissue and lymph nodes (ypT0/Tis, ypN0). | Up to 32 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Objective Response Rate (ORR) | ORR is defined as percentage of participants with Complete Response and Partial Response | Up to 32 weeks |
| Residual Cancer Burden (RCB) | Pathologilly assessed residual cancer burden according to MD Anderson protocol. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Ying Lin, MD | Contact | +8602087755766 | 8212 | linying3@mail.sysu.edu.cn |
| Xiaying Kuang, MD | Contact | +8602087755766 | 8212 | kuangxy5@mail.sysu.edu.cn |
| Name | Affiliation | Role |
|---|---|---|
| Ying Lin, MD | Principal Investigator | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| First Affiliated Hospital, Sun Yat-Sen University | Recruiting | Guangzhou | Guangdong | 510080 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| C000631724 | camrelizumab |
| C000722917 | fluzoparib |
| C520255 | 130-nm albumin-bound paclitaxel |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Fluzoparib | Drug | Fluzoparib |
|
| Nab-paclitaxel | Drug | Nab-paclitaxel |
|
| Up to 32 weeks |
| Event-Free Survival (EFS) | EFS was defined as the time from the date of randomization to the date of events from any cause. | Up to 20 years |
| Overall Survival (OS) | OS was defined as the time from the date of randomization to the date of death from any cause. | Up to 20 years |
| Safety of drugs | Adverse effects of the candidates according to NCI-CTCAE 5.0 | Up to 32 weeks |